<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954263</url>
  </required_header>
  <id_info>
    <org_study_id>0150</org_study_id>
    <nct_id>NCT02954263</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TDâˆ’1439 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma R &amp; D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and
      pharmacodynamics of TD-1439 in healthy adult and elderly subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of adverse events by severity, including changes in vital signs, physical examination, laboratory safety tests, and ECGs.</measure>
    <time_frame>From Day 1 through end of study (Day 25)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of TD-1439 in plasma after multiple doses - peak plasma concentration (Cmax)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of TD-1439 in plasma after multiple doses - time to peak plasma concentration (Tmax)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of TD-1439 in plasma after multiple doses - time to last measurable concentration (Tlast)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of TD-1439 in plasma after multiple doses - area under the plasma concentration vs. time curve from time zero to the last quantifiable concentration (AUC0-t)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of TD-1439 in plasma after multiple doses - area under the plasma concentration vs. time curve from time zero to 24 hours postdose (AUC0-24)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of TD-1439 in plasma after multiple doses - CL/F (oral plasma clearance)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of TD-1439 in plasma after multiple doses - Vz/F (apparent volume of distribution during the terminal phase)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of TD-1439 in plasma after multiple doses - t1/2 (half-life)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of TD-1439 in urine after multiple doses - Ae (amount excreted in urine)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of TD-1439 in urine after multiple doses - Fe (fraction of oral dose excreted in urine)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of TD-1439 in urine after multiple doses - Clr (renal clearance)</measure>
    <time_frame>Day 1 to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic assessments for plasma atrial natriuretic peptide (ANP) concentrations</measure>
    <time_frame>The day before dosing (Day -1) to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic assessments for plasma cyclic guanosine monophosphate (cGMP) concentrations</measure>
    <time_frame>The day before dosing (Day -1) to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic assessments for urine cyclic guanosine monophosphate (cGMP) concentrations</measure>
    <time_frame>The day before dosing (Day -1) to 3 days after last dose (Day 17)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Adults, Elderly Subjects</condition>
  <arm_group>
    <arm_group_label>TD-1439</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1439</intervention_name>
    <arm_group_label>TD-1439</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) 18 to 32 kg/m2 inclusive

          -  Women of child bearing potential must have a negative pregnancy test and either
             abstain from sex or use highly effective methods of birth control

          -  Women of non-childbearing potential are at least 2 years postmenopausal or are
             surgically sterile

          -  Males must abstain from sex or use highly effective methods of birth control

          -  Negative for HIV, and Hepatitis A, B, and C

        Exclusion Criteria:

          -  Female subjects who are pregnant, lactating, breastfeeding or planning to become
             pregnant during the study.

          -  Subjects with a history of angioedema.

          -  Subject has evidence or history of clinically significant allergic (except for
             untreated, asymptomatic, seasonal allergies at time of dosing), hematological,
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or
             neurological disease.

          -  Subject has acute illness (gastrointestinal, infection [e.g., influenza] or known
             inflammatory process)

          -  Subject has bradycardia

          -  Subject has hypertension

          -  Subjects has orthostatic hypotension

          -  Subjects has orthostatic tachycardia

          -  Subject has a known personal or family history of congenital long QT syndrome or known
             family history of sudden death.

          -  Subject has donated blood or blood components or has had blood loss exceeding 400 mL
             within the 90 days prior to Screening.

          -  Additional exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bourdet, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma, US, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple ascending dose (MAD)</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

